Biotech company Microba has partnered with Europe’s largest medical diagnostic services provider SYNLAB to take its world-leading gut microbiome analysis to the European market.

The partnership will provide SYNLAB’s network of Europe-based healthcare professionals with access to new and actionable information on their patients’ health through the co-delivered MyBiome analysis.

It’s the second international partnership for the start-up, which launched Australia’s first detailed gut microbiome analysis in June 2018 using research pioneered by their co-founders at The University of Queensland.

Microba CEO Blake Wills said the partnership would help Microba achieve its goal of improving human health globally.

‘Microba’s partnership with SYNLAB is a great example of 2 international forces coming together to embrace next-generation technologies and support local health care,’ Mr Wills said.

‘It will allow us to expand the reach of our technology into Europe and bring Australian-born innovation into larger overseas markets to positively impact more lives.

‘SYNLAB is a global leader in delivering medical diagnostic services and we are proud to be partnering to add advanced gut microbiome analysis to their portfolio, powered by Microba’s technology.’

Microba has helped more than 10,000 Australians assess their gut health using the company’s award-winning proprietary Metagenomic Analysis Platform (MAP™).

SYNLAB is the market leader in medical diagnostic services in Europe, with a presence in more than 40 countries across 4 continents.

The co-delivered MyBiome analysis will initially be launched in two countries by the end of this year.

TIQ has worked with Microba for a number of years, assisting with their partnership in Korea, access to the US market and helping the company make key connections in Europe.

Queensland Agent General and Trade and Investment Commissioner for Europe Linda Apelt congratulated Microba on their new partnership.

‘We are delighted that we have been able to assist in Microba’s European success through introductions, in particular to European Union’s GDPR (General Data Protection Regulation) expertise that enabled them to achieve the data privacy requirements of the agreement with SYNLAB and therefore to enable this deal,’ Ms Apelt said.

‘We look forward to assisting Microba’s further expansion across Europe.’

The life sciences sector is identified as one of Queensland’s emerging export strengths in the Queensland Trade and Investment Strategy 2017–2022.

To explore export opportunities for the life sciences and biotech sectors, connect with TIQ today.